FDA Discussion Paper – Artificial Intelligence in Drug Manufacturing

As FDA considers the application of its risk-based regulatory framework to the use of AI technologies in drug manufacturing, it has identified in this discussion paper areas for which public feedback would be valuable. 

Read in full HERE